SMTP-7   Click here for help

GtoPdb Ligand ID: 12300

Synonyms: Stachybotrys microspora triprenyl phenol 7 | BIIB131 | orniplabin | SMTP7 | TMS-007
Compound class: Synthetic organic
Comment: SMTP-7 is a natural triprenyl phenol that's produced by Stachybotrys microspora (a fungus) [2]. It is a complex molecule with 5 chiral centers whose absolute stereochemical configuration has been determined using microcrystal electron diffraction (MicroED) [6]. SMTP-7 produces thrombolytic [4], anti-inflammatory, and antioxidant effects. It is being considered as a clinical anti-thrombotic agent for use in stroke patients [5]. The compound has activity as a plasminogen modulator and soluble epoxide hydrolase inhibitor that may offer a novel therapeutic intervention for cardiometabolic diseases [1].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 5
Rotatable bonds 18
Topological polar surface area 177.3
Molecular weight 868.49
XLogP 8.7
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C/C(=C\CC[C@]1(C)Oc2c3CN(C(=O)c3cc(c2C[C@@H]1O)O)CCC[C@H](N1Cc2c(C1=O)cc(c1c2O[C@@](C)(CC/C=C(/CCC=C(C)C)\C)[C@H](C1)O)O)C(=O)O)/CCC=C(C)C
Isomeric SMILES CC(=CCC/C(=C/CC[C@]1([C@H](Cc2c(cc3c(c2O1)CN(C3=O)CCC[C@@H](C(=O)O)N1Cc2c3c(c(cc2C1=O)O)C[C@@H]([C@](O3)(C)CC/C=C(\C)/CCC=C(C)C)O)O)O)C)/C)C
InChI InChI=1S/C51H68N2O10/c1-30(2)14-9-16-32(5)18-11-21-50(7)43(56)26-36-41(54)24-34-38(45(36)62-50)28-52(47(34)58)23-13-20-40(49(60)61)53-29-39-35(48(53)59)25-42(55)37-27-44(57)51(8,63-46(37)39)22-12-19-33(6)17-10-15-31(3)4/h14-15,18-19,24-25,40,43-44,54-57H,9-13,16-17,20-23,26-29H2,1-8H3,(H,60,61)/b32-18+,33-19+/t40-,43-,44-,50-,51-/m0/s1
InChI Key CRNDCHORWGDFGR-PXTWCNKMSA-N
No information available.
Summary of Clinical Use Click here for help
SMTP-7 (BIIB131, TMS-007) is being evaluated as a novel thrombolytic agent for the treatment of acute ischemic stroke. Results from a first-in-human study in healthy volunteers were published in late 2022 [3]. SMTP-7 was well tolerated and no serious adverse events were reported.